Goldman Sachs Maintains Neutral on GeneDx Hldgs, Raises Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes maintains a Neutral rating on GeneDx Holdings (NASDAQ:WGS) but raises the price target from $32 to $54.
October 16, 2024 | 1:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has maintained a Neutral rating on GeneDx Holdings but increased the price target from $32 to $54, indicating a positive outlook despite the neutral stance.
The increase in the price target from $32 to $54 suggests a positive outlook for GeneDx Holdings, which could lead to a short-term price increase. However, the Neutral rating indicates that the analyst does not see a strong buy opportunity, balancing the impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100